Long-term follow-up from the SWOG S0016 trial suggests a substantial cure fraction in advanced follicular lymphoma. The 15-year data estimate a cured cohort of about 42%, with annual relapse rates dropping to roughly 0.6% beyond the 15-year mark. The follow-up also reports 15-year progression-free survival of 34% for the R-CHOP arm, with additional analysis on the impact of adding radioimmunotherapy to CHOP. The coverage notes the deeper control may be tied to stronger initial remissions, while overall survival did not show a clear advantage for the intensification arm and the approach carried a higher rate of myeloid neoplasms. The dataset changes how clinicians may counsel patients early in treatment and could influence payer and trial design assumptions about durable benefit in advanced indolent lymphomas. It also reinforces that long-horizon endpoints remain pivotal when claims of cure are on the table.